EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Netarsudil v/s Ripasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors)

Riddhima Juneja, Taskin Khan, Vishnu Swarup Gupta, Niharika Chaudhary

International Ophthalmology · 12.06.2025 · 45 (1)

DOI: 10.1007/s10792-025-03590-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Ophthalmology, online erschienen am 12.06.2025. Verfasst von Riddhima Juneja und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, HAH Centenary Hospital, Hamdard Institute of Medical Sciences and Research, New Delhi, 110062, India. riddhimajuneja@gma…. Hauptthemen laut MEDLINE: Intraocular Pressure, Glaucoma, Open-Angle, Sulfonamides, Isoquinolines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To compare the intraocular pressure (IOP) lowering effect and safety of topical netarsudil 0.02% once daily with topical ripasudil 0.4% twice daily in primary open angle glaucoma (POAG) patients. METHODS: A prospective, comparative, randomized study conducted on 140 eyes of patients diagnosed to have POAG, in a tertiary care hospital of Northern India. Patients divided into groups, A and B in a 1:1 ratio and were treated with ripasudil 0.4% or netarsudil 0.02% respectively and followed up. The mean diurnal IOP noted at 3rd week and 3rd month comparing it from baseline values, with their side effects. RESULTS: At 3rd month, meandiurnal IOP for ripasudil 0.4% group ranged from 19.22 to 20.69 mmHg whereas for netarsudil group it was 17.11-18.47 mmHg, an intergroup statistically significant difference in IOP of 2.3 mmHg (p < 0.0001) noted. At 3rd month the difference from baseline was 2.77 mmHg (p = 0.048) for ripasudil and 4.64 mmHg (p = 0.001) for netarsudil. At the end of 3 months the adverse events were seen less in group B than group A (59.8% and 66.7% respectively. Eye irritation followed by conjunctival hyperemia was seen. Overall incidence of adverse events was 32.9% and 44.3% for topical netarsudil and ripasudil respectively. CONCLUSION: Topical netarsudil 0.02% once daily was well tolerated with fewer side effects and in reducing IOP than topical ripasudil 0.4% twice daily dosing in POAG patients. Netarsudil 0.02% once daily may be considered an important option for the IOP control in POAG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intraocular PressureGlaucoma, Open-AngleSulfonamidesIsoquinolinesBenzoatesrho-Associated Kinasesbeta-AlanineHumansMaleFemaleProspective StudiesMiddle AgedOphthalmic SolutionsAgedTreatment OutcomeFollow-Up StudiesTonometry, OcularDose-Response Relationship, DrugAdultProtein Kinase Inhibitors

Stichwörter der Autor:innen

Conjunctival hyperemiaIntraocular pressureNetarsudilPrimary open angle glaucomaRho-kinase inhibitorsRipasudilVisual analogue pain scale

Substanzen

K-115netarsudilSulfonamidesOphthalmic SolutionsIsoquinolinesBenzoatesrho-Associated Kinasesbeta-AlanineProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, HAH Centenary Hospital, Hamdard Institute of Medical Sciences and Research, New Delhi, 110062, India. riddhimajuneja@gmail.com.
  • Department of Ophthalmology, HAH Centenary Hospital, Hamdard Institute of Medical Sciences and Research, New Delhi, 110062, India.

Zitieren

APA

Juneja, R., Khan, T., Gupta, V. S., & Chaudhary, N. (2025). Netarsudil v/s Ripasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors). International Ophthalmology, 45(1). https://doi.org/10.1007/s10792-025-03590-7

Vancouver

Juneja R, Khan T, Gupta VS, Chaudhary N. Netarsudil v/s Ripasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors). International Ophthalmology. 2025;45(1). doi:10.1007/s10792-025-03590-7

BibTeX
@article{Juneja2025,
  author = {Juneja, Riddhima and Khan, Taskin and Gupta, Vishnu Swarup and Chaudhary, Niharika},
  title = {Netarsudil v/s Ripasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors)},
  journal = {International Ophthalmology},
  year = {2025},
  volume = {45},
  number = {1},
  doi = {10.1007/s10792-025-03590-7}
}
Kostenlos starten →